HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. HALO has a Growth Style Score of B, forecasting year-over-year ...

In the past year, shares of Halozyme have rallied 65.8% against the industry’s decline of 3.5%. Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Analysts have recently evaluated Halozyme Therapeutics and provided 12-month price targets. The average target is $66.78, accompanied by a high estimate of $75.00 and a low estimate of $53.00. Holding ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce ...

Analog Devices (NASDAQ:ADI) led chips stocks higher on Wednesday after its positive quarterly results and outlook kept analysts bullish, while Lam Research (NASDAQ:LRCX) made key announcements ...